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DownAberrations in oncogenes and tumor suppressors frequently affect the activity of critical signal transduc-
tion pathways. To analyze systematically the relationship between the activation status of protein networks
and other characteristics of cancer cells, we did reverse phase protein array (RPPA) profiling of the NCI60 cell
lines for total protein expression and activation-specific markers of critical signaling pathways. To extend the
scope of the study, we merged those data with previously published RPPA results for the NCI60. Integrative
analysis of the expanded RPPA data set revealed five major clusters of cell lines and five principal proteomic
signatures. Comparison of mutations in the NCI60 cell lines with patterns of protein expression showed sig-
nificant associations for PTEN, PIK3CA, BRAF, and APC mutations with proteomic clusters. PIK3CA and
PTEN mutation enrichment were not cell lineage-specific but were associated with dominant yet distinct
groups of proteins. The five RPPA-defined clusters were strongly associated with sensitivity to standard
anticancer agents. RPPA analysis identified 27 protein features significantly associated with sensitivity to pac-
litaxel. The functional status of those proteins was interrogated in a paclitaxel whole genome small interfering
RNA (siRNA) library synthetic lethality screen and confirmed the predicted associations with drug sensiti-
vity. These studies expand our understanding of the activation status of protein networks in the NCI60 cancer
cell lines, demonstrate the importance of the direct study of protein expression and activation, and provide a
basis for further studies integrating the information with other molecular and pharmacological characteristics
of cancer. Mol Cancer Ther; 9(2); 257–67. ©2010 AACR.Introduction
The NCI60 cell line collection is the most extensively
characterized panel of cancer cell lines in existence. It
consists of 60 human cancer cell lines derived from nine
different tumor types, including leukemia (LN), colon
(CO), lung [non-small cell lung cancer (NSCLC)], central
nervous system (CNS), renal (REN), melanoma (ME),
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on January 6, 2014.mct.aacrjournals.org loaded from In part because of the extensive pharmacological charac-
terization of NCI60, they have frequently been used as
test samples for emerging technologies and methods
of analysis (2–8). Global gene expression patterns and
alterations of DNA copy numbers in the NCI60 collection
have been assessed by a number of microarray-based
technologies, and the resulting data sets have been
pooled and analyzed together with pharmacological
characteristics of the cell lines, providing a comprehen-
sive interaction map between pharmacological and
genetic characteristics of the cells (9–11).
Although those studies have yielded much useful infor-
mation, there is a strong rationale for complementing
them with a direct assessment of the expression and acti-
vation of proteins involved in critical signal transduction
pathways. During the progression of cancer, many signal-
ing proteins are activated through genetic, epigenetic,
and post-translational events. Approaches based on gene
expression signatures have been used to interrogate gain-
of-function or loss-of-function events during tumor
progression (12, 13), but such analyses cannot assess
translational regulation. Indeed, previous studies have
shown frequent andmarked discordance between mRNA
expression levels and protein levels in tumors and cell
lines (14–17). Moreover, kinase signaling pathways are
generally regulated by post-translational modifications,257
 © 2010 American Association for Cancer Research. 
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of the phosphorylated and unphosphorylated forms of
signaling proteins should improve our understanding of
the molecular and pharmacologic characteristics of the
NCI60 cell lines.
The reverse phase protein array (RPPA) is a powerful
technology that provides quantitative measurement of
protein expression and activation. Previously RPPA was
used to profile the expression of 94 proteins in the NCI60
cell line collection (14, 18). Although that study provided
a number of interesting findings, insight into the role of
signaling networks was critically limited by the lack of
antibodies that recognize activation-specific modifica-
tions of proteins. We have developed RPPA assays to
assess post-translational modifications that reflect the
activation status of many proteins involved in kinase sig-
naling (19–22). Recently we used this technique to mea-
sure the levels of phosphorylated AKT (P-AKT) in the
NCI60 cell lines, and found an unexpected difference in
P-AKT levels in cell lines with PTEN loss as compared
with those with PIK3CA mutations (22). Here we report
the RPPA analysis of the NCI60 for an expanded panel of
antibodies, including activation-specific markers of other
signaling pathways and additional markers related to
PI3K-AKT signaling. We merged these results with the
existing RPPA data of the NCI60, and demonstrate a rel-
atively high degree of reproducibility and correlation of
overlapping antibodies between the data sets. The inte-
grated RPPA data set was used to assess the association
of tumor type with protein expression and activation,
extending previous studies that did not include phos-
pho-proteins (14, 18). We also did the first systematic
evaluation of protein features associated with the onco-
genic mutations present in the NCI60 (23). Finally, we
did a pilot analysis to identify proteins that correlate with
sensitivity to standard anticancer agents. The functional
significance of proteins associated with taxol sensitivity
was assessed by reviewing results of a paclitaxel
whole-genome small interfering RNA (siRNA) synthetic
lethality screen, and validated the predictive nature of
these associations.7 http://www.dtp.nci.nih.gov
8 http://rana.lbl.gov/EigenSoftware.htm
9 http://www.dtp.nci.nih.gov
10 http://www.r-project.comMaterials and Methods
Reverse Phase Protein Array Studies
Two independent data sets of RPPA data were gener-
ated. An initial analysis (MDA_Pilot) was done by ex-
tracting proteins from cell pellets that were generated
and provided by the National Cancer Institute (NCI). A
subsequent analysis (MDA_CLSS) was done using viable
cells obtained from the NCI and that were grown in our
laboratory. Cells were maintained in RPMI 1640 supple-
mented with 5% fetal bovine serum at 37°C in a humid-
ified 5% CO2 atmosphere, and proteins were harvested
when the cells reached ∼70% confluence. These cells,
and the cell pellets provided by the NCI, were lysed with
buffer containing 1% Triton X-100, 50 mM Hepes pH 7.4,Mol Cancer Ther; 9(2) February 2010
on January 6, 2014.mct.aacrjournals.org Downloaded from 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM
NaF, 10 mM NaPPi, 10% glycerol, 1 mM Na3VO4, and
Complete Protease Inhibitor Cocktail (Roche Diagnos-
tics). Protein supernatants were isolated using standard
methods (22), and protein concentration was determined
by BCA assay (Pierce). Samples were diluted to a uni-
form protein concentration, and then they were dena-
tured in 1% SDS for 10 minutes at 95°C. Samples were
stored at −80°C until use. RPPA analysis was done as de-
scribed previously (20–22). A logarithmic value reflecting
the relative amount of each protein in each sample was
generated for analyses. MDA_Pilot RPPA analysis was
done using a total of 34 antibodies, and the MDA_CLSS
analysis used 99 antibodies (Supplementary Table S1).
The RPPA data set “NCI” was previously reported (14),
and the publicly available data were downloaded from
the NCI Developmental Therapeutics Program website.7
Each of the three RPPA data sets was independently nor-
malized and mean-centered. The data sets were then
merged into a single data set for subsequent analyses.
Statistical Analysis
Hierarchical cluster analysis was done using Cluster
and Treeview.8 The reproducibility and correlation of re-
sults were tested by calculating Pearson Correlation coef-
ficients. The associations between protein features and
mutation status within cell line clusters were determined
by χ2 and Fisher's exact testing. Associations with drug
sensitivity were assessed using the GI50 data for the
NCI60 cell lines.9 Analyses of statistical associations
between drug sensitivity and RPPA clusters were done
by one-way ANOVA. Proteins significantly correlated
with paclitaxel sensitivity were selected based on Pear-
son Correlation Coefficients (P < 0.05 by the t-statistic).
All statistical analyses were done in the R language
environment.10Results
Integration and Analysis of RPPA Data Sets
Two new RPPA data sets for the NCI60 cell line set
were generated. “MDA_PILOT” RPPA analysis was done
using cell lysates generated from cell pellets provided by
the NCI Developmental Therapeutics Program. That
study included measurement of 34 protein features (Sup-
plementary Table S1). A second study, “MDA_CLSS,”
was done using cell lysates generated by independently
growing the NCI60 cell lines in our laboratory using tis-
sue culture conditions recommended by the NCI, with
lysis of cells done directly on tissue culture plates. TheMolecular Cancer Therapeutics
 © 2010 American Association for Cancer Research. 
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which overlapped with those in the MDA_Pilot (Supple-
mentary Table S1; Supplementary Fig. S1A). A compari-
son of the two RPPA analyses showed that 20 out of 26
(76.9%) of the shared proteins had statistically significant,
positive correlations (Supplementary Fig. S1B). Because
those results supported the feasibility of merging indepen-
dent RPPA data sets, and in order to maximize the strength
of the proteomic analysis of the NCI60, the two data sets
were integrated with previously published RPPA data on
the NCI60 for 94 proteins.11 Each data set was individually
normalized and mean-centered prior to merging.
We first compared results for the three independent
RPPA data sets. Five proteins (CTNNB1, CDH1, ESR1,
MAPK1, and PRKCA) were common to all three sets
(Supplementary Fig. S1C). Despite the many possible
sources of variability and systematic differences, the re-
sults for CTNNB1 and CDH1 showed remarkably high
concordance among all the three independent sets. For
example, Pearson correlation coefficients for CTNNB1
expression levels were 0.92 (NCI versus MDA PILOT,
P < 0.00001), 0.86 (NCI versus MDA_CLSS, P <
0.00001), and 0.84 (MDA_PILOT versus MDA_CLSS,
P < 0.00001). The direct interaction of those proteins is
well-established (24), and the correlation of protein ex-
pression levels is consistent with previous studies that
showed that loss of CDH1 results in decreased levels
of CTNNB (25). The results for MAPK1 showed the
weakest correlation between NCI data and MDA_PILOT
data (r = 0.16, P = 0.22), but, the correlation between
MAPK1 levels in the different sets was higher than those
between MAPK1 and the other shared protein features
(Supplementary Fig. S1C). The correlation of ESR1 and
PRKCA expression between the two M.D. Anderson data
sets was very high (PRKCA: r = 0.917, P < 0.00001; ESR1:
r = 0.93, P < 0.00001), but there was only moderate corre-
lation of the M.D. Anderson sets with NCI data (PRKCA:
MDA_PILOT versus NCI r = 0.23, P = 0.07; MDA_CLSS
versus NCI r = 0.24, P = 0.06; ESR1: MDA_PILOT versus
NCI r = 0.29, P = 0.02; MDA_CLSS versus NCI r = 0.26,
P = 0.04). The weak correlations might reflect any numb-
ers of factors, such as differences in tissue culture condi-
tions, methods for quantitating data, or specificity of
antibodies used at the two institutions. For example, the
antibody used to measure PRKCA in MDA_PILOT and
MDA_CLSS recognizes an epitope that is reported to be
specific to PRKCA, whereas the antibody used by the
NCI is noted by its manufacturer to recognize PRKCB
as well.12 Despite those sometimes-weak correlations,
measurements of a given protein in the three independent
data sets were almost always as nearest neighbors in
unsupervised hierarchical clustering analysis of the
shared proteins (Supplementary Fig. S1C). That observa-11 http://www.dtp.nci.nih.gov
12 http://www.bdbiosciences.ca
www.aacrjournals.org
on January 6, 2014.mct.aacrjournals.org Downloaded from tion supported the strategy of using the combined data
from the three RPPA experiments to study the proteins
associated with other features of the NCI60 cell lines.
Unsupervised hierarchical clustering of the integrated
RPPA data representing 222 protein features encompass-
ing 167 unique features revealed five distinct clusters of
cell lines (Fig. 1). The clusters generally reflected the dif-
ferent tumor types in the NCI60 cell line set. Cluster 1 is
mainly composed of brain tumor lines (CNS). The mem-
bers of cluster 2 are mostly lung (NSCLC) and renal cell
carcinomas (REN). Cluster 3 includes all of the colon
(CO) cancer cell lines, as well as a few cell types from
other lineages. Cluster 4 includes all of the leukemia
(LK) cell lines. Cluster 5 is entirely composed of melano-
ma (ME), including MDA-MB-435. Although MDA-MB-
435 was initially thought to be a breast cancer cell line, a
variety of genotypic and phenotypic data confirm that it
is melanoma in origin, a somewhat diverged version of
M14 melanoma (6, 26, 27). Cluster 2 included four of sev-
en ovarian cell lines, including OV-CAR8_ADR-RES,
which had originally been thought to be a derivative of
MCF7 breast cancer and then was renamed an agnostic
NCI_ADR-RES by DTP. Microsatellite fingerprinting
and other molecular analyses indicate that it is actually
a drug-resistant derivative of OV-CAR8 (26). Breast
(BR) lines were scattered throughout the clusters, sug-
gesting phenotypic heterogeneity. Overall four tumor
types (CNS, ME, LK, and CO) were significantly enriched
within clusters, whereas the remaining five tumor types
(BR, NSCLC, OVR, REN, and PRO) were not asso-
ciated with particular clusters by χ2 or Fisher's exact tests
(Table 1).
We identified five groups of proteins (“A” to “E”) that
were up-regulated in the clusters of cell lines described
above (Supplementary Fig. S2). The proteomic signature
A, characteristic of melanoma, includes total protein
levels of several components of the PI3K-AKT signaling
network (PI3K.p110, AKT, FRAP1, GSK3), but does not
include any activation-specific markers for this pathway.
Signature A also includes total proteins in the MAPK
signaling pathway (HRAS, MAPK1, MAP2K2), and an
activation-specific marker (MEK1&2_pS217_S221).
Signature B, which is leukemia-specific, includes proteins
involved in cellular proliferation (MCM7, PCNA, GRB2,
EIF4E, IRS1, HNRNPA1, c-MYC, c-MYC_pT58S62) and
cell cycle progression (CDC2, CDK4, CDK7, CCNB1,
CDKN1A), compatible with the high proliferative rates
of leukemia cell lines. Signature C consists mainly of
colon cancer lines and includes proteins involved in cell
adhesion (CTNNB1, CDH1, CDH3). CDH1 (MDA_PILOT
data) shows the most dramatic increase in expression
in cluster C (97fold increase versus the other clusters).
Signature D reflects proteins highly expressed in cell
line cluster 2 with mixed cell lineages. Signature D
includes a group of tightly correlated proteins: PRKCA,
PRKCA_pS567, CAV1, C-JUN, EGFR, and TGM1. Finally,
signature E is CNS-specific and reflects activation of the
PI3K-AKT pathway. Many activation-specific proteinsMol Cancer Ther; 9(2) February 2010 259
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Published OnlineFirst February 2, 2010; DOI: 10.1158/1535-7163.MCT-09-0743 forms in the pathway were expressed at high levels in the
cluster (AKT_pS473, AKT_pT308, GSK3α&β_ pS21_S9,
FOXO3A_pS318_S321 , RPS6KB1_pS235_S236 ,
RPS6KB1_pS240_S244).
Association of Mutations with Proteomic Signatures.
Recently, the mutation status of 24 cancer-related genes
was determined for all of the NCI60 cell lines and iden-
tified oncogenic mutations in 20 of the genes (23). To
assess systematically the relationship between cancer-
prevalent mutations and patterns of protein expression
and activation, we measured the associations between
those mutations and the proteomic signatures of the
NCI60 (Fig. 2A). When contingency table analysis with
five-group χ2 and Fisher's exact tests was applied, theMol Cancer Ther; 9(2) February 2010
on January 6, 2014.mct.aacrjournals.org Downloaded from mutations in four genes (PTEN, BRAF, PIK3CA, APC)
were significantly enriched, in particular, RPPA-derived
clusters (Table 2). Mutations in BRAF were significantly
enriched in cluster 5 (7 out of 8 cell lines, P = 0.006 by
χ2 test). Homozygous mutations of PTEN were most
enriched in cluster 1 (P = 0.048 in Fisher's exact test).
The presence of any mutation in PTEN was also enriched
in cluster 1, but this was not statistically significant (6 out
of 12 cell lines, P = 0.136 by χ2 test). Mutation in PIK3CA
was enriched in cluster 3 (6 out of 7 cell lines), although
that trend did not reach statistical significance (P = 0.103
by χ2 test). Similarly, mutations in APC, BRCA2, and
SMAD4 were more abundant in cluster 3, but their en-
richment did not reach statistical significance. Because
the five clusters of cell lines identified by protein features
partly reflected tumor types in the NCI60, we carried out
nine-group χ2 and Fisher's exact tests to assess the asso-
ciation between mutation status and cancer cell type
(Supplementary Table S2). As predicted by previous
studies, mutation of BRAF was significantly enriched in
the melanoma cell lines (P = 0.010 by χ2 test), whereas
mutations in APC and BRCA2 were significantly ©Table 1. Association study of cancer cell types
with integrated RPPA data of NCI 60 cell linesCell Type 2010 Americχ2
statisticMole
an Associatioχ2
P valuecular Cance
n for CanceFisher's exact
test P valueBreast 3.024286 0.553769 0.794203
CNS* 19.48026 0.000632 0.000721
Colon* 15.00478 0.004691 0.008337
Leukemia* 23.21053 0.000115 0.000123
Lung 4.386675 0.356197 0.442148
Melanoma* 24.31579 6.90E-05 7.34E-05
Ovary 5.485714 0.240988 0.356018
Prostate 5.114551 0.275744 0.648159
Renal 9.127127 0.057999 0.06333NOTE: Five group χ2 test and Fisher's exact test of cell
types against RPPA-defined clusters were done.
*Cell types showing significant enrichment in specific
clusters.Figure 1. RPPA analysis of the NCI 60 RPPA cell lines and tumor
types. Unsupervised hierarchical clustering analysis of the integrated
proteomic data representing 222 protein features (167 unique features)
from three independent NCI60 RPPA data sets is shown. The RPPA
data sets were independently normalized and mean centered before
integration. Categorization of the cells into one of five clusters is
indicated by CLUSTER below the cell line names. The cancer cell type
from which each cell line originated is indicated by CELL-TYPE below the
color-coded label for CLUSTER. The groups of proteins that demonstrate
increased expression characteristic of the different cell line clusters
are indicated to the left (Signature A to E). The RPPA data set source for
each protein is indicated to the right of the heat map. Proteins assessed
in more than one data set are also indicated (Same Antibody). Labels for
all cell lines in each cluster are included in Figure 2; labels for all proteins
are included in Supplementary Fig. S2.r Therapeutics
r Research. 
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Published OnlineFirst February 2, 2010; DOI: 10.1158/1535-7163.MCT-09-0743 enriched in colon cancer cell lines (P = 0.0038 and P =
0.037, respectively). Among the four mutated genes
(PTEN, BRAF, PIK3CA, APC) most significantly associat-
ed with RPPA clusters, BRAF and APC were associated
with specific cancer cell lineages. Mutations in PTEN and
PIK3CA did not associate with specific cancer cellwww.aacrjournals.org
on January 6, 2014.mct.aacrjournals.org Downloaded from lineages, but they were the most highly associated with
specific, but distinct, proteomic signatures.
To identify unique associations between mutations
and RPPA cell line clusters, we did “two-group” χ2 and
Fisher's exact tests in which each cluster was compared
with the rest of cell lines for enrichment with uniqueFigure 2. Association of the NCI60
RPPA signatures with mutations
and drug sensitivity. A, cell lines
are organized by the results of
unsupervised clustering analysis
of the RPPA data (Fig. 1). The
names and order of the cell lines
in each cluster are indicated above
the dendogram. RPPA cluster and
the cell type are indicated below
the cell line labels. Mutations
identified in each cell line are
indicated in the table below
(orange squares, homozygous
mutations; brown squares,
heterozygous mutations). The heat
map represents the negative
log10 GI50 values of 10 standard
anticancer agents. GI50 values
were median-centered (red, high
value, i.e., sensitive; green, low
value, i.e., resistant). B, results
of five group one-way ANOVA
analysis of the GI50 values for
each of the agents for the NCI60
cell lines. Y-axis, negative log 10
P values. The colored horizontal
lines indicate various P value
cutoffs.Mol Cancer Ther; 9(2) February 2010 261
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Published OnlineFirst February 2, 2010; DOI: 10.1158/1535-7163.MCT-09-0743 mutations. Homozygous mutations in PTEN were sig-
nificantly associated with cluster 1 (P = 0.024, χ2 test;
P = 0.016, Fisher's exact test), whereas cluster 2 was nota-
ble for a lack of mutation in PTEN (P = 0.095, by χ2 test;
Supplementary Tables S3 and S4). Mutations in PIK3CA
(P = 0.039, χ2 test; P = 0.023, Fisher's exact test), APC
(P = 0.005; P = 0.003), BRCA2 (P = 0.034; P = 0.022), and
SMAD4 (P = 0.034; P = 0.022) were enriched in cluster 3.
Cluster 4 was not associated with any mutation set, prob-
ably because leukemias are frequently characterized by
chromosomal rearrangements of oncogenes rather than
missense mutations. Mutations in BRAF were significant-
ly enriched in cluster 5 (P = 0.001, χ2; P = 0.001, Fisher's
exact test), consistent with the high prevalence of that
mutation in melanoma.
The opposing associations of two clusters (clusters 1
and 2) with mutation in PTEN are intriguing. The clus-
ters have similar proteomic signatures, as shown by their
proximity in the unsupervised hierarchical clustering
(Fig. 1). To identify protein features that distinguish clus-
ter 1 and cluster 2, we carried out two-sample t tests and
found that expression of six protein features (KRT18,
KRT19, PTEN [MDA PILOT], PTEN [MDA CLSS],
MGMT, TGM1) and phosphorylation of six protein fea-
tures (AKT_pT308 [MDA_CLSS], AKT_pS473 [MDA_
CLSS], AKT_pS473 [MDA_PILOT], MAPK14_pT180.
Y182, RPS6KA1_pT389_S363, TSC2_pT1462) were signif-
icantly different (P < 0.001; Supplementary Fig. S3).
PTEN expression was significantly higher (9.4fold and
8.6fold) in cluster 2, whereas phosphorylation of AKTMol Cancer Ther; 9(2) February 2010
on January 6, 2014.mct.aacrjournals.org Downloaded from was significantly higher in cluster 1 (AKT_pS473:
4.95fold, AKT_pT308: 3.675fold). Although PTEN muta-
tions were enriched in cluster 1, approximately 50% of
the cell lines in that cluster do not harbor PTEN muta-
tions and show normal PTEN expression. Thus, other
genetic events are also sufficient to result in the observed
pattern of protein expression, and/or contribute to the
pattern of protein expression observed in the PTEN-null
cell lines in the cluster.
Protein Signatures, Mutation Status, and Drug Sensi-
tivity.We next investigated the relationship between pro-
teomic profiles of the NCI60 cell lines and their sensitivity
to anticancer agents. Analysis of the GI50 values for the
NCI60 cell lines for a set of commonly used agents
showed marked differences in average sensitivity among
the five clusters of cell lines (Fig. 2A; Supplementary Fig.
S4). Cluster 1, which is characterized by increased levels
of activation-specific markers in the PI3K-AKT pathway,
showed high sensitivity to rapamycin, an inhibitor of
mTOR. In contrast, cluster 5, which is characterized by
expression of total, but not activation-specific markers
in the PI3K-AKT pathway, was less sensitive to rapamy-
cin. Cluster 2, which demonstrates similarity to cluster 1
by hierarchical clustering but lacks the signature of
PI3K-AKT pathway activation, was also less sensitive
to rapamycin. Cluster 2 is characterized by lower sensi-
tivity to paclitaxel and doxorubicin in relation to other
clusters. Cell lines in cluster 4 showed high sensitivity
to most of the chemotherapeutic agents. Paclitaxel (P =
0.0026 by one-way ANOVA), carboplatin (P = 0.0028),Table 2. Association study of mutation status with integrated RPPA data of NCI 60 cell linesMutation Total © 2010 AmHomozygous
χ2 P value Fisher's exact test P value χ2 P valueMole
erican AssociatioFisher's exact test P valueP53 0.927015 0.935214 0.555924 0.575416
P16 0.450216 0.427948 0.250227 0.230189
RB 0.343613 0.441297 0.353376 0.417028
PTEN* 0.135962 0.109034 0.059305 0.047797
PIK3CA 0.103316 0.198385 NaN 1
LKB1 0.394828 0.519535 0.754997 0.913696
APC* 0.028054 0.058023 0.253053 0.634973
SMAD4 0.102952 0.173347 0.592418 1
VHL 0.696682 0.860656 0.696682 0.860656
RAS 0.240045 0.306594 0.665184 0.808537
B-RAF* 0.006084 0.01228 0.032172 0.039891
FLT3 0.217584 0.283333 NaN 1
BRCA1 0.592418 1 NaN 1
BRCA2 0.102952 0.173347 NaN 1
HER2 0.293537 0.636066 NaN 1
EGFR 0.293537 0.119672 0.217584 0.283333
PDGFR-a 0.217584 0.283333 NaN 1
B-CATENIN 0.451529 0.483333 NaN 1NOTE: Five group χ2 test and Fisher's exact test of mutation status against RPPA-defined clusters were done.
*Mutations showing significant enrichment in specific clusters.cular Cancer Therapeutics
n for Cancer Research. 
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Published OnlineFirst February 2, 2010; DOI: 10.1158/1535-7163.MCT-09-0743 and cisplatin (P = 0.0038) showed the most significant
differences in sensitivity of the cells as a function of cell
cluster (Fig. 2B).
Figure 3A shows the variation in GI50 values for pac-
litaxel within each RPPA-defined cluster. Most of the cells
in cluster 4 were highly sensitive to paclitaxel. Cluster 2
was least sensitive to paclitaxel but showed a very wide
range of drug responses suggesting that other factors are
responsible for the heterogeneity. Nine group one-way
ANOVA analysis for estimation of the influence of cancer
cell type on paclitaxel showed significant differences (P =
0.0041) implying that drug sensitivity differences are re-
lated in part to cell lineage differences. Three cell types,
CNS, colon, and leukemia, showed the most sensitivity
to paclitaxel, whereas renal cell carcinoma showed the
least sensitivity (Supplementary Fig. S5). The melano-
mas, lung cancers, ovarian cancers, and renal cell carcino-
mas showed wide ranges of drug sensitivity, reflecting
the apparent heterogeneity of those cell types.
Comparisons of RPPA data with GI50 values for pacli-
taxel across the cell lines identified 27 protein features
significantly correlated by Pearson correlation coefficient
(P < 0.05; Table 3). Two proteins (CCND1 and Phospho-
P38 MAPK) showed significant Pearson correlations in
two independent RPPA experiments; thus 25 unique fea-
tures were identified. Expression of CCND1 showed the
most negative correlation with paclitaxel sensitivity (r =
−0.452, P = 0.00033). Levels of transglutaminase 2
(TGM2), lung-resistance related protein (MVP), clathrin
adaptor protein 50 (AP2M1), annexin A2 (ANXA2), n-
cadherin (CDH2), STAT1, and keratin 19 (KRT19) were
also significantly correlated with resistance (Fig. 3B). Me-
tastasis inhibition factor NM23 (NME1) showed the high-
est positive correlation with paclitaxel sensitivity (r =
0.364 P = 0.00464). MCM7, ADNP, GSK3, SMN1, and
MYC expression levels also correlated positively with
paclitaxel sensitivity. To assess the functional effects of
those genes on paclitaxel sensitivity, we reviewed the re-
sults of a whole-genome siRNA synthetic lethality screen
done with paclitaxel in a human lung cancer cell line
(28). In that screen, the effect of each gene on paclitaxel
sensitivity was assessed by determining the ratio of the
cell viability score for the combination of gene knockdown
in the presence and the absence of paclitaxel. A paclitaxel
to carrier ratio less than 1 suggests that gene knockdown
results in increased sensitivity to paclitaxel, and thus sup-
ports that gene is a mediator of paclitaxel resistance. Over-
all, the proteins significantly associated with resistance to
paclitaxel by RPPA had a lower ratio of paclitaxel to car-
rier cell viability than the proteins associated with sensi-
tivity (P = 0.03; Fig. 3C). Eleven of the 13 proteins that
correlated with paclitaxel resistance by RPPA had a pac-
litaxel to carrier ratio <1, and 5 of those proteins showed
a statistically significant (P < 0.05) difference in growth in
the presence of paclitaxel (Table 3). Among the proteins
correlated with sensitivity to paclitaxel, only 5 of the 12
had a ratio <1, and none showed statically significant dif-
ference in growth.www.aacrjournals.org
on January 6, 2014.mct.aacrjournals.org Downloaded from Assessment of the expression levels of the significantly
correlated proteins across the NCI60 cell lines reflected
the differences in paclitaxel sensitivity observed across
the RPPA-based clusters (Fig. 3D). TGM2 and ANXA2
were highly expressed in cluster 2 (least sensitive to pac-
litaxel), whereas they were expressed at the lowest levels
in cell lines in cluster 4 (most sensitive to paclitaxel).
MYC, MCM7, and NME1 were expressed at the highest
levels in cluster 4 (as part of RPPA signature B for cluster
4). We surmise that the differences in sensitivity to pacli-
taxel result in part from differences in protein signaling
that are the cumulative outcomes of differences in cell
type and mutation status.
Discussion
There is a great need to improve our understanding of
the molecular characteristics and heterogeneity of cancer.
The NCI60 is a powerful tool for such studies, due to the
wealth of data publicly available about those cell lines (1–
6). Although much is known about the DNA, RNA, and
pharmacologic aspects of the lines, data on protein ex-
pression and activation is much more limited. Previous
proteomic analyses of the NCI60 have yielded important
information, including the marked lack of correlation be-
tween protein and mRNA expression levels for several
families of proteins (14, 18). However, those studies did
not include a direct assessment of the activation status of
signaling pathways. We have extended the available
body of data available on the NCI60 by performing RPPA
analysis using activation-specific markers for several
cell-signaling pathways. We have used those data in con-
cert with other available proteomic data to extend our
understanding of the patterns of protein expression and
activation that characterize different tumor types, cancer-
prevalent mutations, and drug sensitivities.
Comparison of the protein expression data from three
independent RPPA studies of the NCI60 demonstrate
that proteomic signatures are relatively robust and repro-
ducible, even when generated in completely independent
laboratories. Supporting the robustness of the proteomic
analysis of a relatively small number of features, the
RPPA-derived clusters of the NCI-60 cell lines largely re-
capitulate the results observed by whole genome mRNA
profiling (6). That conclusion is most clearly indicated by
assignment of the MDAMB 435 cell line to the melanoma
cluster, as has been shown in a number of transcriptional
profiling studies and microsatellite fingerprinting (6, 26).
The addition of activation-specific markers provides fur-
ther information about the distinctions between the
groups of cell lines. For example, although clusters 1
and 2 are closely related by hierarchical cluster analysis,
there are marked differences between the two clusters in
the levels of activation-specific markers in the PI3K-AKT
signaling pathway (Fig. 1; Supplementary Fig. S3). In
contrast, the two clusters did not differ significantly in
total protein expression levels for the majority of the
pathway components, such as AKT. In addition, clusterMol Cancer Ther; 9(2) February 2010 263
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Published OnlineFirst February 2, 2010; DOI: 10.1158/1535-7163.MCT-09-0743 5 was characterized by increased total-protein levels of
several components of the PI3K-AKT pathway, but it
did not feature increased activation-specific pathway
markers. The functional significance of that additionalMol Cancer Ther; 9(2) February 2010
on January 6, 2014.mct.aacrjournals.org Downloaded from information is reflected in an increased sensitivity to
rapamycin, an inhibitor of signaling downstream of
AKT, in cluster 1 in comparison with clusters 2 and 5.
Thus, the inclusion of activation-specific markers providesMolecular Cancer Therapeutics
 © 2010 American Association for Cancer Research. 
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Published OnlineFirst February 2, 2010; DOI: 10.1158/1535-7163.MCT-09-0743 insight into the functional differences between these oth-
erwise closely-related groups of cells.
In this study we did the first systematic comparison of
the oncogenic mutations in the NCI60 with their proteo-
mic profiles. As described above, although clusters 1 andwww.aacrjournals.org
on January 6, 2014.mct.aacrjournals.org Downloaded from 2 share many protein features, only cluster 1 has a proteo-
mic signature that includes elevated phospho-protein
levels of several components of the PI3K-AKT pathway
(AKT, TSC2, GSK3, S6, FOXO3A). Cluster 1 is highly en-
riched with PTEN mutations. Although activation ofTable 3. Proteins that correlate with paclitaxel sensitivityProtein RPPA
CategoryRPPA
Versus
−Log GI50
r ValueRPPA
Versus
−Log GI50
P valueGene
SymbolsiRNA
Average
Viability
(Paclitaxel) ©siRNA
Average
Deviation
(Paclitaxel) 2010 AmersiRNA
Average
Viability
(Carrier)ican AssosiRNA
Average
Deviation
(Carrier)Mol Cance
ciation fosiRNA
Ratio
(Paclitaxel/
Carrier)r Ther; 9(2) F
r Cancer ResiRNA
Paclitaxel
Versus
Carrier
P valueCCND1 Resistant −0.452 <0.001 CCND1 0.651 0.044 0.839 0.026 0.776 0.023
TGM2 Resistant −0.411 0.001 TGM2 0.678 0.007 0.752 0.016 0.902 0.007
MVP Resistant −0.370 0.004 MVP 0.688 0.035 0.783 0.022 0.878 0.0644
AP2M1 Resistant −0.349 0.007 AP2M1 0.766 0.021 0.872 0.031 0.878 0.052
CDH2 Resistant −0.345 0.007 CDH2 0.684 0.028 0.779 0.016 0.878 0.038
ANXA2 Resistant −0.344 0.008 ANXA2 0.669 0.074 0.760 0.052 0.881 0.261
KRT19 Resistant −0.328 0.011 KRT19 0.644 0.021 0.689 0.044 0.935 0.292
STAT1 Resistant −0.326 0.012 STAT1 0.761 0.030 0.877 0.018 0.868 0.016
TRADD Resistant −0.298 0.022 TRADD 0.897 0.032 1.070 0.060 0.838 0.035
PGR Resistant −0.289 0.026 PGR 0.935 0.047 0.931 0.014 1.004 0.931
JAK1 Resistant −0.265 0.042 JAK1 1.039 0.037 1.183 0.030 0.879 0.019
KRT18 Resistant −0.260 0.047 KRT18 1.042 0.004 1.025 0.037 1.017 0.698
STAT6 Resistant −0.260 0.046 STAT6 0.766 0.024 0.810 0.034 0.946 0.274
S6 Sensitive 0.28 0.032 RPS6 0.831 0.008 0.789 0.027 1.053 0.134
MYC; Sensitive 0.288 0.027 MYC 0.710 0.032 0.814 0.046 0.873 0.086
MYCpT58 Sensitive 0.296 0.023
P-MAPK Sensitive 0.303 0.019 MAPK1 0.892 0.025 0.926 0.012 0.963 0.191
(P-MAPK) Sensitive 0.303 0.019 MAPK3 0.869 0.039 0.814 0.023 1.068 0.191
GSK3α/β Sensitive 0.306 0.019 GSK3 1.116 0.063 1.140 0.049 0.979 0.714
(GSK3α/β) Sensitive 0.306 0.019 GSK3 1.152 0.080 1.099 0.054 1.048 0.531
P-JNK Sensitive 0.309 0.017 MAPK8 1.079 0.047 0.986 0.016 1.095 0.078
SMN1 Sensitive 0.318 0.014 SMN1 0.596 0.287 0.825 0.042 0.722 0.369
ADNP Sensitive 0.323 0.013 ADNP 1.081 0.053 1.053 0.041 1.027 0.627
P-P38 Sensitive 0.325 0.012 MAPK14 0.914 0.050 0.886 0.018 1.032 0.518
MCM7 Sensitive 0.351 0.006 MCM7 0.885 0.016 0.940 0.029 0.941 0.097
NME1 Sensitive 0.364 0.005 NME1 0.958 0.040 0.949 0.012 1.010 0.800
Median Resistant −0.328 0.011 0.761 0.030 0.839 0.030 0.879 0.052
Median Sensitive 0.306 0.019 0.892 0.040 0.926 0.029 1.010 0.191NOTE: For antibodies that recognize more than one protein (i.e., GSK3αβ recognizes both GSK3α and GSK3β), the results for
siRNA against each protein is presented. Both Total and Phospho MYC protein levels correlated with sensitivity to paclitaxel.
For siRNAs that showed a significant difference (P < 0.05) for growth in the presence of paclitaxel as compared the carrier, the
related proteins and P values presented in bold text.Figure 3. Protein factors associated with paclitaxel responsiveness in the NCI60 panel. A, box-plot analysis of negative log10 GI50 values for paclitaxel in
each RPPA-defined cluster. B, Pearson correlation coefficients for proteins significantly correlated with paclitaxel response across the NCI 60 cell lines
(P values for the Pearson correlation < 0.05). Positive values indicate that high expression is associated with high sensitivity; negative values reflect
association with paclitaxel resistance. C, effect of proteins significantly associated with paclitaxel sensitivity on relative growth of lung cancer cells in the
presence of paclitaxel. The results of a previously published whole genome siRNA library ± paclitaxel synthetic lethality screen (28) were reviewed. Y-axis,
ratio of relative growth for cells in the presence of siRNA with paclitaxel to siRNA with vehicle. The dotted line indicates paclitaxel to carrier ratio of 1.
The red bars indicate the median of each group. Filled triangle, significant difference (P < 0.05) for growth in the presence of paclitaxel versus carrier.
D, expression of proteins significantly correlating with paclitaxel GI50 values in the NCI60. Cells are organized by the results of unsupervised hierarchical
clustering of the RPPA data (Fig. 1). Heat maps show protein expression levels negatively (upper panel) and positively (lower panel) correlated with sensitivity.
The RPPA cluster and cell type for each cell line are indicated. The −log10 GI50 value for paclitaxel for each cell line is presented above the heat map.ebruary 2010 265
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Published OnlineFirst February 2, 2010; DOI: 10.1158/1535-7163.MCT-09-0743 PI3K-AKT signaling is significantly associated with the
mutation status of PTEN, it is not associated with the
mutation status of PIK3CA (clusters 1 and 3). This obser-
vation is consistent with our previous analysis of a much
smaller set of proteins, including phospho-AKT, in the
NCI60 cell lines, as well as an analysis of an independent
panel of breast cancer cell lines and clinical specimens
(20, 22). Thus, the protein expression data and mutation
status complement each other to provide understanding
not available from either alone.
There is a great need for biomarkers to predict respon-
siveness to anticancer agents. A number of previous anal-
yses have used the abundant pharmacologic data for the
NCI60 cell lines to test associations between drug sensi-
tivity and DNA copy numbers, DNA methylation,
mRNA and miRNA expression, and oncogenic mutations
(3, 29–32). We did a pilot analysis of the expanded RPPA
protein expression data with drug sensitivity for a panel
of 10 commonly used agents. In addition to the previous-
ly noted association of rapamycin sensitivity with
increased expression of activation-specific markers in
the PI3K-AKT pathway, we examined protein features
associated with sensitivity to several commonly used
cytotoxic agents. We identified 25 unique protein features
significantly associated with sensitivity to paclitaxel. The
correlations with sensitivity and resistance by RPPA
matched functional results for the proteins in a published
paclitaxel whole genome siRNA synthetic lethality screen
(28). Those findings indicate the likely benefit of addi-
tional studies that expand the approach to the larger
collection of agents for which sensitivity is known for
the NCI60 cell lines. In addition, it will be important to
integrate the proteomic data with other molecular char-Mol Cancer Ther; 9(2) February 2010
on January 6, 2014.mct.aacrjournals.org Downloaded from acteristics of the cell lines for such analyses, as has
proved beneficial in multiple studies (17, 31–33).
In conclusion, this study again demonstrates the tre-
mendous potential of the RPPA technology to provide in-
formation about the status of protein networks in cancer.
Our analyses suggest that the reproducibility of the
RPPA data are such that assimilating data from multiple
sources is feasible, and that may help overcome the lim-
itation of the relatively small number of markers that can
be assessed in individual studies. The inclusion of phos-
phorylation-specific antibodies in our RPPA analysis im-
proves the ability to assess protein networks functionally.
However, many other functional aspects of protein net-
works remain to be assessed. The data here supports
the hypothesis that such direct analyses of protein net-
works may improve our understanding of the underpin-
nings of cancer. When integrated with other available
data, the information may lead to more effective thera-
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